BioSpace News Archive

The isothermal nucleic acid amplification technology/INAAT market has been estimated to experience numerous growth opportunities in the following years.

Endovenous laser therapy has been used for the treatment of varicose veins with significant success, especially in adult populations with saphenous insufficiency.

The sexually transmitted diseases testing market has been projected to grow at a noticeable speed in the foreseeable years.

Retinal Biologics Market value surpassed US$ 19.96 Bn in 2022 and projected to grow at 10.7% y-o-y in 2019, as per a new Future Market Insights study.

Sequana Medical NV announces its financial results for the year ended 31 December 2021, and provides a business update and an outlook for the remainder of 2022.

Captor Therapeutics S.A. announces the molecular targets of one of its core pipeline projects designated CT-01, which is focused on the development of TPD therapy for hepatocellular carcinoma.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that CEO Nawal Ouzren will attend in person two investor meetings in April 2022.

PureTech Health plc announced the publication of preclinical proof-of-concept demonstrating that PureTech’s Glyph platform can enhance the oral bioavailability of buprenorphine, a clinically-validated opioid replacement therapy, further expanding the range of clinically-validated drug classes shown to be amenable to the Glyph technology.

Engitix Ltd, a biotechnology company developing a portfolio of programmes in fibrosis and solid tumours using its proprietary human extracellular matrix platform, entered into an agreement with Takeda to expand an existing collaboration to now include the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.

Deerfield Partner Andrew ElBardissi, M.D. and Petrichor Partner Patrick Lally to Join Aurion Biotech Board Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, announced it has secured a $120 million financing with top-tier biotech and ophthalmology investors.